Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025

Key TakeawaysHims' third-quarter results topped expectations, driven in part by revenue from its weight-loss drugs.The company said it plans to launch a generic version of a Novo Nordisk diabetes and weight-loss drug as early as 2025.Bank of America said Hims has “an opportunity to continue to drive user growth," and raised its price target for the company's stock. Hims & Hers Health (HIMS) reported third-quarter results that topped analysts' expectations Monday, lifting its shares, as the company said t pl ...